Germany – Research and development services and related consultancy services – Produktion von Lentivirus in GMP-Qualität
- Buyer
- Charité - Universitätsmedizin Berlin
- Country
- Germany
- Published
- 2026-10-19
- Deadline
- 2026-11-17
- Type
- cn-standard
- Status
- Open to bid
- Category
- CPV 73000000
Description
Die Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin schreibt die Produktion von Lentivirus zur Transduktion von humanen Zellen in GMP-Qualität inklusive entsprechende Dokumentation sowie eine Stabilitätsstudie aus. Es bestehen gesonderte Anforderungen nach dem Berliner Ausschreibungs- und Vergabegesetz (BerlAVG), siehe Vergabeunterlagen. Nähere Informationen können den auf der Vergabeplattform der Charité (https://vergabeplattform.charite.de) zur Verfügung gestellten Unterlagen entnommen werden.
The buyer's description as published on TED (Tenders Electronic Daily). The full notice is at the source.
Around this tender
- Closes in 26 days, on 2026-11-17.
- Charité - Universitätsmedizin Berlin has 21 notices on this site, 14 of them open now, the earliest published 2026-09-24. See them all.
- One of 49 open Research & development tenders in Germany on this site; where a value is published, the median is 338.4k USD.
- Work under the same CPV group (730) is open in 21 other countries: United Kingdom (28), Norway (15), Poland (15), Netherlands (5), Belgium (5) and 16 more.
Counted from the notices this site holds, which reach back about a month - not everything a buyer has ever published.
Get new Research and development services and related consultancy tenders in Germany by email
One free weekly email with the newest matching notices, each with at least a few days left to respond. No account, unsubscribe in one click.
Other open Research & development tenders in Germany
About this record
This notice was published via TED (Tenders Electronic Daily) and indexed automatically. Figures and dates are reproduced as published at source; always confirm against the original before acting on a deadline.